3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
18
Bevacizumab
14
Carboplatin
11
Standard of Care
9
Nivolumab
9
Pemetrexed
7
Exercise
7
Cyclophosphamide
7
Cetuximab
7
atezolizumab
6
Temozolomide
6
Cisplatin
6
durvalumab
5
Prednisone
5
Paclitaxel
5
Fluorouracil
5
Doxorubicin
5
130-nm albumin-bound paclitaxel
5
abemaciclib
4
Leucovorin
4
Gemcitabine
4
Docetaxel
4
Dexamethasone
4
Blood Specimen Collection
4
venetoclax
3
temsirolimus
3
olaparib
3
ibrutinib
3
enzalutamide
3
dostarlimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.